Orthofix Medical Secures $275 Million Credit Facility to Support Growth Strategies

Orthofix Medical Secures $275 Million Credit Facility to Fuel Growth Initiatives

Orthofix Medical Inc., a leading global medical technology firm based in Lewisville, Texas, has recently secured a significant credit agreement that grants the company up to $275 million in a senior-secured term loan. This loan, which features a 48-month interest-only period, is designed to provide non-dilutive capital, thereby enhancing Orthofix's financial flexibility as the company aims to prioritize profitable growth. The initial tranche of the loan, amounting to $160 million, is earmarked for retiring an existing credit facility, while the remaining $115 million will become available after January 1, 2025. Chief Financial Officer Julie Andrews stresses that this refinancing is a pivotal move for Orthofix, allowing the company to secure more favorable terms and facilitate ongoing investments in its growth strategy.

In light of recent financial performance, Orthofix demonstrates a promising trajectory, having reported steady improvements throughout 2024. The company showcases a notable increase in adjusted EBITDA and has achieved positive free cash flow, indicating effective cash management practices. Massimo Calafiore, the President and CEO, highlights that the company’s strategic focus on profitable growth is yielding impressive results. With plans to sharpen commercial efforts and enhance operational discipline, Orthofix aims for margin expansion as it progresses into 2025 and beyond. The confidence expressed by its lending partners, including Oxford Finance and K2 HealthVentures, further reinforces the belief in Orthofix's leadership and growth strategy.

The new credit facility not only positions Orthofix for sustainable growth but also aligns with its mission of enhancing mobility and improving the quality of life for patients worldwide. As the company continues to execute its growth priorities, it maintains its full-year 2024 net sales guidance of $795 million to $800 million and projects a non-GAAP adjusted EBITDA between $64 million and $69 million. Additionally, Orthofix has entered into a record number of earnout agreements for its 7D FLASH™ Navigation System, underscoring its commitment to innovation and market leadership.

Orthofix Medical's proactive financial maneuvers and strong performance metrics reflect a robust strategy that prioritizes both operational excellence and the wellbeing of patients. As further details of the credit agreement are set to be disclosed in upcoming SEC filings, the firm remains optimistic about its future growth potential and patient-centric innovations.